BrightSpring Q2 Beat, Raised View Affirms Specialty-Led Growth But Valuation Remains Rich

What happened

BrightSpring Health Services delivered Q2 2026 earnings and revenues above consensus, driven by continued specialty pharmacy growth and expanding provider services margins. Management raised its full-year 2026 outlook, reinforcing the mix-shift narrative that has propelled earnings even as total prescriptions face pressure. The results suggest that Q1’s script decline and SG&A surge were transitory, with specialty and infusion demand offsetting IRA-related headwinds in the home and community pharmacy business. However, the stock remains priced for perfection at ~45x trailing EPS, and the July-announced raised guidance may already be discounted after the recent rally. Moreover, the overhang of KKR’s remaining ~13.7% stake and the pattern of secondary offerings without full buyback absorption continue to weigh on risk-reward.

Implication

Investors should view the Q2 beat as confirmation that the specialty/infusion mix shift can drive earnings growth even as total scripts decline, but the raised guidance does little to resolve the structural issues of elevated SG&A, policy-driven pharmacy pressure, and recurring sponsor secondaries. The stock’s P/E of ~45x leaves no room for error, and any deceleration in specialty growth or a post-lockup sell-down by KKR could quickly reverse gains. Until there is evidence of script stabilization and a clear path to organic margin expansion, the risk-reward is unfavorable; we’d look for a pullback toward the $55 area before becoming constructive.

Thesis delta

The Q2 beat and raised outlook strengthen the company’s operating trajectory and partially address prior concerns about script volume and cost control. However, the investment thesis only improves modestly because valuation remains stretched, sponsor overhang persists, and the reliance on mix shift rather than broad-based volume growth introduces execution risk. We maintain a WAIT rating but the threshold for an upgrade would now require sustained script growth and a clear reduction in sponsor selling.